Welcome to our dedicated page for Artelo Biosciences news (Ticker: ARTL), a resource for investors and traders seeking the latest updates and insights on Artelo Biosciences stock.
Artelo Biosciences, Inc. (NASDAQ: ARTL) is a clinical-stage pharmaceutical company developing proprietary therapeutics that modulate lipid-signaling pathways, including the endocannabinoid system. The ARTL news feed on Stock Titan aggregates company announcements, scientific updates, financing transactions, and regulatory disclosures that shape the outlook for its drug development programs.
Investors and observers following Artelo’s news can track progress across a diversified pipeline that includes ART27.13 for cancer anorexia and weight loss, ART26.12 as a Fatty Acid Binding Protein 5 (FABP5) inhibitor for chemotherapy-induced peripheral neuropathy and other potential indications, and ART12.11, a patented cocrystal composition of cannabidiol (CBD) and tetramethylpyrazine (TMP). Company press releases highlight interim clinical data from the Cancer Appetite Recovery Study (CAReS), Phase 1 results for ART26.12, and preclinical findings supporting the therapeutic potential of FABP inhibition and pharmaceutical-grade CBD formulations.
The ARTL news stream also features peer-reviewed publication announcements, conference presentations at oncology and cannabinoid-focused meetings, and corporate developments such as executive appointments, cooperation agreements with shareholders, and capital-raising activities via public offerings, private placements, and at-the-market programs. Regulatory and listing-related updates, including communications about Nasdaq listing compliance, are disclosed through Form 8-K filings and associated press releases.
By reviewing Artelo Biosciences news on this page, readers can monitor key milestones in its clinical trials, scientific validation of its FABP and CBD platforms, and corporate actions that influence its financial and strategic position. Bookmark this feed to follow how Artelo’s lipid-signaling and endocannabinoid-targeted programs evolve through clinical, scientific, and capital markets events over time.
Artelo Biosciences (Nasdaq: ARTL) reported clinical progress across three programs and fiscal 2025 year-end results dated February 24, 2026. Key clinical highlights include a positive Phase 1 SAD for ART26.12, positive interim Phase 2 CAReS data for ART27.13, and favorable UK MHRA guidance for ART12.11.
Financially, R&D was $5.4M, G&A $6.0M, net loss $12.9M ($12.52 per share), and cash and investments totaled $0.6M as of December 31, 2025.
Artelo Biosciences (Nasdaq: ARTL) commented on the Dec 23, 2025 White House Executive Order creating a Medicare pilot for cannabidiol (CBD) reimbursement and structured data collection.
Artelo said the initiative could improve access and generate data to inform research and potential Medicaid expansion. The company highlighted ART12.11, its patented CBD–tetramethylpyrazine cocrystal, stating superior oral bioavailability, more consistent pharmacokinetics, and enhanced efficacy signals in preclinical anxiety and depression models. Artelo reported the Drug Enforcement Agency indicated ART12.11 would not be considered a controlled substance and said it is prepared to complete final steps to advance ART12.11 into human clinical trials.
Artelo Biosciences (Nasdaq: ARTL) announced a peer‑reviewed publication (Dec 3, 2025) reporting that intraperitoneal dosing of its proprietary FABP5 inhibitor SBFI103 produced robust anxiolytic and antidepressant‑like effects in a validated chronic‑stress rat model.
Key experimental findings include single‑dose reductions in anxiety‑ and depression‑like behaviors with no locomotion or memory deficits, increased hippocampal expression of endocannabinoid‑related receptors CB2, GPR55, TRPV1, prevention of stress‑linked declines in depression biomarkers, and blockade of chronic‑stress effects on hippocampal neurogenesis.
The company funded the research; authors controlled study design and conclusions. Artelo said the data strengthen the rationale to advance FABP5 inhibitors (including ART26.12) toward human studies.
Artelo Biosciences (Nasdaq: ARTL) reported Q3 2025 results and provided a business update on Nov 12, 2025. Key clinical highlights include interim Phase 2 CAReS results for ART27.13 showing mean +6.4% weight gain at top dose versus -5.4% on placebo and +4.2% lean body mass, plus a Notice of Allowance from the European Patent Office covering the intended commercial formulation through 2041.
Development progress: ART26.12 completed SAD with a MAD protocol being finalized; ART12.11 first-in-human expected 1H 2026 after MHRA guidance. Q3 financials: R&D $1.3M, G&A $1.8M, net loss $3.1M (loss per share $3.97), cash and investments $1.7M; gross equity proceeds of $0.4M (ATM) and $3.0M (public offering).
Artelo Biosciences (Nasdaq: ARTL) announced the publication on November 4, 2025 of a peer‑reviewed review, “The Emerging Role of Fatty Acid Binding Protein 3 (FABP3) in Cancers,” in Drug Discovery Today with lead author Dr. George Warren.
The article is the third in a trilogy on FABP isoforms 3, 5, and 7 and highlights evidence that FABP3 promotes tumorigenic processes via lipid metabolism, hypoxia, and ferroptosis. The review notes that both genetic and pharmacological inhibition of FABP3 showed therapeutic benefits in preclinical cancer models. Artelo says it maintains a portfolio of selective, dual, and pan FABP3/5/7 inhibitors and is advancing its lead program, ART26.12, targeting FABP5 for pain while exploring oncology opportunities.
Artelo Biosciences (Nasdaq: ARTL) named Mark Spring, CPA, as Chief Financial Officer, effective November 1, 2025.
Mr. Spring has served as a financial consultant to Artelo since December 2024 and brings 30 years of life‑sciences financial leadership, including interim CFO and CFO roles at multiple commercial and development‑stage companies and significant M&A and licensing experience. The appointment is presented as strengthening financial leadership as Artelo advances its clinical pipeline and corporate growth initiatives.
Artelo Biosciences (Nasdaq: ARTL) will present expanded clinical data on ART26.12 and interim Phase 2 data on ART27.13 at the 8th Annual Cannabinoid & Endocannabinoid Drug Development Summit on October 15–16, 2025 in Boston.
Key findings: ART26.12 single ascending dose study showed safety at single doses up to 1050 mg, predictable linear plasma exposure, and potential dosing flexibility in fed or fasted states. ART27.13 Phase 2 interim data in cancer anorexia showed treated patients (up to 1300 µg/day on average) gained >b>6% body weight versus placebo patients who lost an additional 5%, with a similar tolerability profile to earlier stages to date.
Artelo Biosciences (Nasdaq: ARTL), a clinical-stage pharmaceutical company, has completed its previously announced public offering, raising $2.0 million in gross proceeds. The offering consisted of 441,210 shares of common stock priced at $4.40 per share and pre-funded warrants to purchase up to 13,335 shares at $4.399 per warrant.
The company has granted underwriters a 45-day option to purchase up to an additional 68,181 shares to cover over-allotments. R.F. Lafferty & Co. served as the sole book-running manager for the offering, which was conducted under Artelo's existing shelf registration statement.
Artelo Biosciences (Nasdaq: ARTL), a clinical-stage pharmaceutical company, has announced the pricing of a $2.0 million public offering. The offering consists of 441,210 shares of common stock priced at $4.40 per share and pre-funded warrants to purchase up to 13,335 shares at $4.399 per warrant.
The company has granted underwriters a 45-day option to purchase up to an additional 68,181 shares. The offering, managed by R.F. Lafferty & Co. as the sole book-runner, is expected to close on October 1, 2025. The securities are being offered through a shelf registration statement previously filed with and declared effective by the SEC.
Artelo Biosciences (Nasdaq: ARTL), a clinical-stage pharmaceutical company, has announced a proposed underwritten public offering of common stock and/or pre-funded warrants. The offering will be managed by R.F. Lafferty & Co., Inc. as the sole book-running manager.
The securities will be offered through a "shelf" registration statement on Form S-3 that was previously filed and declared effective by the SEC on July 14, 2023. The final terms, size, and completion of the offering will depend on market conditions.